4-[1-(3-chlorophenyl)-1H-1,2,3-triazole-4-carbonyl]thiomorpholine
Structure Info
- Chemspace ID
- CSSS00104595677 (In-Stock Screening Compounds)
- CAS
- 951612-19-4
- MFCD
- MFCD15129559
- IUPAC Name
- 4-[1-(3-chlorophenyl)-1H-1,2,3-triazole-4-carbonyl]thiomorpholine
- Mol formula
- C13H13ClN4OS
- Mol weight
- 309 Da
- Catalog Number(s)
- 951612-19-4, AA01KYME, AG01KYP6, AR01KZE6, BA57506, BBV-108683047, BD287743, BNB61219, BUP05240, C614813, CSC104595677, CSCR00064365695, CSCR01006651864, EBC-06829, EN300-157186, G60114, HY-113763, IBS-E0686216, L524-0366, LN00315997, M22217, PBMR202988, PV-001825152476, PV-002187434442, ST01L05Y, SY498135, T8570, TS-09829, TX01KZUU, Y229442, Y3226090, Z1723635500, ZXC357611, a1_4616_37151, s_22____848246____9107588, s_527____848264____9107590
- Copy structure to query editor
- SMILES
- INCHI
- INCHI key
- MOL
Properties
- LogP
- 2.33
- Heavy atoms count
- 20
- Rotatable bond count
- 2
- Number of rings
- 3
- Carbon bond saturation, Fsp3
- 0.307
- Polar surface area (Å)
- 51
- Hydrogen bond acceptors count
- 3
- Hydrogen bond donors count
- 0
![Chemical structure of 4-[1-(3-chlorophenyl)-1H-1,2,3-triazole-4-carbonyl]thiomorpholine (C13H13ClN4OS) - CSSS00104595677](/st/structure/200/1844f8ad4b2be5f4a305590802e3d88d/ClC1%253DCC%253DCC%2528%253DC1%2529N1C%253DC%2528N%253DN1%2529C%2528%253DO%2529N1CCSCC1.png "C13H13ClN4OS")
- Zoom the structure
- CSSS00104595677
Items Overall 43 items from 7 suppliers
| Supplier | Lead time | Ships from | Purity | Pack | Price, $ | Qty |
|---|---|---|---|---|---|---|
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 1 mg | 53.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 2 mg | 54.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 5 mg | 55.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 10 mg | 66.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 20 mg | 81.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 25 mg | 90.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 30 mg | 100.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 35 mg | 108.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 40 mg | 116.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 45 mg | 122.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 50 mg | 136.00 | |
| Enamine Bioactive Compounds | 10 days | Ukraine To: | 90 | 75 mg | 208.00 | |
Description: 4-[1-(3-Chlorophenyl)-1H-1,2,3-triazole-4-carbonyl]thiomorpholine has an inhibitory effect on fibroblast growth factor inducible 14. | ||||||
| MedChemExpress | 10 days | United States To: | 99 | 1 mg | 140.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 5 mg | 300.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 25 mg | 790.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 50 mg | 1,100.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 100 mg | 1,450.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 1 ml | 330.00 | |
Description: Names: L524-0366; Product Description: L524-0366 is a specific, dose-dependent TWEAK-Fn14 inhibitor. L524-0366 specifically binds to the Fn14 surface with a KD of 7.12 μM, competitively inhibiting the binding of Fn14 to TWEAK (inhibition rate reaching 16%). L524-0366 inhibits TWEAK-induced glioma cell migration without potential cytotoxic effects; Target: TNF Receptor; CAS: 951612-19-4 | ||||||
| MedChemExpress EU | 10 days | Sweden To: | 99 | 1 mg | 140.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 5 mg | 300.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 25 mg | 790.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 50 mg | 1,100.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 100 mg | 1,450.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 1 ml | 330.00 | |
Description: Names: L524-0366; Product Description: L524-0366 is a specific, dose-dependent TWEAK-Fn14 inhibitor. L524-0366 specifically binds to the Fn14 surface with a KD of 7.12 μM, competitively inhibiting the binding of Fn14 to TWEAK (inhibition rate reaching 16%). L524-0366 inhibits TWEAK-induced glioma cell migration without potential cytotoxic effects; Target: TNF Receptor; CAS: 951612-19-4 | ||||||
| Enamine Ltd. | 15 days | Ukraine To: | 90 | 50 mg | 170.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 1 mg | 113.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 5 mg | 247.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 10 mg | 378.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 25 mg | 653.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 50 mg | 892.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 100 mg | 1,180.00 | |
Description: L524-0366 is a selective Fn14 receptor antagonist that exerts its effects through competitive binding to the Fn14 receptor. L524-0366 specifically binds to the Fn14 receptor surface, with a KD of 7.12 μM. At a concentration of 10 μM, L524-0366 completely inhibits TWEAK-induced glial cell migration and exhibits no cytotoxicity at concentrations below 50 μM. L524-0366 possesses antitumor and anti-inflammatory activity and is widely used in research on diseases such as cancer.; CAS: 951612-19-4 | ||||||
| TargetMol CN | 30 days | China To: | 99 | 1 mg | 113.00 | |
| TargetMol CN | 30 days | China To: | 99 | 5 mg | 247.00 | |
| TargetMol CN | 30 days | China To: | 99 | 10 mg | 378.00 | |
| TargetMol CN | 30 days | China To: | 99 | 25 mg | 653.00 | |
| TargetMol CN | 30 days | China To: | 99 | 50 mg | 892.00 | |
| TargetMol CN | 30 days | China To: | 99 | 100 mg | 1,180.00 | |
Description: L524-0366 is a selective Fn14 receptor antagonist that exerts its effects through competitive binding to the Fn14 receptor. L524-0366 specifically binds to the Fn14 receptor surface, with a KD of 7.12 μM. At a concentration of 10 μM, L524-0366 completely inhibits TWEAK-induced glial cell migration and exhibits no cytotoxicity at concentrations below 50 μM. L524-0366 possesses antitumor and anti-inflammatory activity and is widely used in research on diseases such as cancer.; CAS: 951612-19-4 | ||||||
| TargetMol EU | 30 days | Netherlands To: | 99 | 1 mg | 113.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 5 mg | 247.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 10 mg | 378.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 25 mg | 653.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 50 mg | 892.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 100 mg | 1,180.00 | |
Description: L524-0366 is a selective Fn14 receptor antagonist that exerts its effects through competitive binding to the Fn14 receptor. L524-0366 specifically binds to the Fn14 receptor surface, with a KD of 7.12 μM. At a concentration of 10 μM, L524-0366 completely inhibits TWEAK-induced glial cell migration and exhibits no cytotoxicity at concentrations below 50 μM. L524-0366 possesses antitumor and anti-inflammatory activity and is widely used in research on diseases such as cancer.; CAS: 951612-19-4 | ||||||
For a custom pack size or bulk
please drop us a line:Enquire
please drop us a line:Enquire